Teladoc Health Reports Q4 Earnings with Mixed Results

Teladoc Health reports Q4 earnings, revealing mixed performance with revenue slightly exceeding expectations but a greater net loss than analysts predicted. An uncertain outlook may impact investor sentiment and stock prices.

Date: 27-02-2025

AI Rating: 4

Earnings Report Overview

Teladoc Health has released its fourth-quarter earnings for fiscal 2024, showcasing a mix of results that could influence stock prices going forward.

Revenue Growth

The company reported revenue of $640.5 million, slightly beating analysts' expectations of $639 million. However, this figure reflects a 3% decline compared to the same quarter in the previous year, indicating a potential concern for investors about the company's growth trajectory.

Net Income

Teladoc experienced a net loss of $0.28 per share, which was worse than the expected loss of $0.26 per share. This greater-than-expected loss might negatively affect investor confidence and indicate ongoing challenges within the business.

Free Cash Flow (FCF)

Teladoc's free cash flow for the quarter stood at $56.3 million, which is a significant decrease of 39.8% compared to the previous year’s figure of $93.6 million. This decline could lead to concerns about the company's ability to maintain liquidity and fund its operations moving forward.

Adjusted EBITDA

In addition, the company's Adjusted EBITDA was reported at $74.8 million, which represents a 34.6% drop from Q4 of 2023. This downward trend in profitability metrics reflects broader operational challenges that could pressure stock prices.

Forward Outlook

Looking ahead, Teladoc has forecasted revenue for 2025 between $2.468 billion and $2.576 billion, slightly below the $2.570 billion it reported in 2024. The forecasted adjusted EBITDA range of $278 million to $319 million also suggests lower expectations compared to the previous year. These predictions may heighten concerns among investors regarding the company's growth potential in the coming year.

Conclusion

Overall, while Teladoc managed to meet revenue expectations, the declines in net income, free cash flow, and EBITDA, alongside a cautious outlook, could potentially lead to a negative impact on investor sentiment and stock prices.

Stocks: TDOC